Vyth-Dreese FA - Search Results

1

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.

van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM. van den Boorn JG, et al. Among authors: vyth dreese fa. J Invest Dermatol. 2009 Sep;129(9):2220-32. doi: 10.1038/jid.2009.32. Epub 2009 Feb 26. J Invest Dermatol. 2009. PMID: 19242513 Free article.

2

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.

Tjin EP, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KL, van der Horst CM, Bos JD, Nieweg OE, Kroon BB, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM. Tjin EP, et al. Among authors: vyth dreese fa. Clin Cancer Res. 2011 Sep 1;17(17):5736-47. doi: 10.1158/1078-0432.CCR-11-0230. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750202

3

In situ visualization of antigen-specific T cells in cryopreserved human tissues.

Vyth-Dreese FA, Kim YH, Dellemijn TA, Schrama E, Haanen JB, Spierings E, Goulmy E. Vyth-Dreese FA, et al. J Immunol Methods. 2006 Mar 20;310(1-2):78-85. doi: 10.1016/j.jim.2005.12.011. Epub 2006 Feb 2. J Immunol Methods. 2006. PMID: 16487538

4

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

Tjin EP, Krebbers G, Meijlink KJ, van de Kasteele W, Rosenberg EH, Sanders J, Nederlof PM, van de Wiel BA, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM. Tjin EP, et al. Among authors: vyth dreese fa. Cancer Immunol Res. 2014 Jun;2(6):538-46. doi: 10.1158/2326-6066.CIR-13-0097. Epub 2014 Mar 10. Cancer Immunol Res. 2014. PMID: 24894091

5

Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas.

Schepers K, Toebes M, Sotthewes G, Vyth-Dreese FA, Dellemijn TA, Melief CJ, Ossendorp F, Schumacher TN. Schepers K, et al. J Immunol. 2002 Sep 15;169(6):3191-9. doi: 10.4049/jimmunol.169.6.3191. J Immunol. 2002. PMID: 12218137

6

Idiotypic immunoglobulin secretion by human B cell non-Hodgkin's lymphomas is related to the expression of the interleukin-2 receptor.

Vyth-Dreese FA, Dellemijn TA, Hekman A, Melief CJ. Vyth-Dreese FA, et al. Leukemia. 1988 Apr;2(4):231-5. Leukemia. 1988. PMID: 3129622

7

Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.

Vlasveld LT, Hekman A, Vyth-Dreese FA, Melief CJ, Sein JJ, Voordouw AC, Dellemijn TA, Rankin EM. Vlasveld LT, et al. Cancer Immunol Immunother. 1995 Jan;40(1):37-47. doi: 10.1007/BF01517234. Cancer Immunol Immunother. 1995. PMID: 7530170 Free PMC article. Clinical Trial.

8

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.

Vlasveld LT, Hekman A, Vyth-Dreese FA, Rankin EM, Scharenberg JG, Voordouw AC, Sein JJ, Dellemijn TA, Rodenhuis S, Melief CJ. Vlasveld LT, et al. Br J Cancer. 1993 Sep;68(3):559-67. doi: 10.1038/bjc.1993.386. Br J Cancer. 1993. PMID: 8353046 Free PMC article. Clinical Trial.

9

Functional and molecular characterization of B cell line derived interleukin-1 alpha.

Vyth-Dreese FA, Hekman A, Wijffels J, Geertsma M, Dellemijn TA, Dosda J, Melief CJ, Bertoglio J. Vyth-Dreese FA, et al. Leukemia. 1989 Aug;3(8):585-92. Leukemia. 1989. PMID: 2787453

10

Role of LFA-1/ICAM-1 in interleukin-2-stimulated lymphocyte proliferation.

Vyth-Dreese FA, Dellemijn TA, Frijhoff A, van Kooyk Y, Figdor CG. Vyth-Dreese FA, et al. Eur J Immunol. 1993 Dec;23(12):3292-9. doi: 10.1002/eji.1830231235. Eur J Immunol. 1993. PMID: 7903074

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

53 results

Search Page